Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum) in more than 100 markets, further reinforcing its leading global position in antibiotics.
Product Name : Zinnat
Product Type : Antibiotic
Upfront Cash : Undisclosed
November 10, 2021
Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Sandoz B2B
Deal Size : $500.0 million
Deal Type : Divestment
GSK to Sell Cephalosporin Antibiotics Business to Sandoz
Details : Cephalosporin manufacturing will transfer from GSK sites to Sandoz following a four-year manufacturing and supply agreement (MSA) and subsequent transfer of manufacturing operations.
Product Name : Zinnat
Product Type : Antibiotic
Upfront Cash : Undisclosed
November 02, 2021
Lead Product(s) : Cefuroxime Axetil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Sandoz B2B
Deal Size : $500.0 million
Deal Type : Divestment
Reset All
